Vaxart, Inc. (NASDAQ:VXRT) Q4 2022 Earnings Call Transcript

Phil Lee: Thank you, Brant. James, this one is on norovirus for you on the clinical study. So the question is the norovirus again, presuming you obtained positive data from Phase 2 studies, when would the end-of-Phase 2 with FDA meeting take place? And what’s your timeline to design and initiate a Phase 3 trial? James?

James Cummings: Thanks. Presuming we have positive data from the Phase 2 studies, we expect an end-of-Phase 2 Meeting would be next year 2024. The Phase 3 trial could begin as early as next year as well and that will be in concert with guidance from the agency. Over.

Brant Biehn: Excellent. Thank you, James. Andrei, this one is going to be for you and really just talking about funding. What’s the prospect for U.S. and international government funding whether it’s from the U.K., BARDA, et cetera. Andrei, over to you.

Andrei Floroiu: Well, this is — it’s a difficult question to answer particularly now as we perceive the interest and attention of various governments and governmental agencies have shifted. So it’s hard to predict what governments are going to do. We remain in contact with important agencies, both here in the U.S. and abroad, and we continue to believe that our oral pill vaccine platform could play a transformational role in fighting pandemics in general. So again, we continue to have those communications, but it’s hard to predict the outcome.

Brant Biehn: Thank you, Andrei. Phil, this is another question on share price for you. When there’s, a number of them, I’ll just answer one, but there’s a lot of questions about the same thing. Will there be a reverse split to get the shares over $1? If so, what’s the ratio? Phil, I hand that over to you.

Phil Lee: Sure, Brent. So we believe we have key catalysts that would really drive the potential interest in our stock price in the next two quarters, as we mentioned earlier on this call, those costs do include a top line data readout for our Phase 2 dose-ranging study as well as the top line data for our Phase 2 challenge study for norovirus. In terms of a reverse split, we don’t believe we need one at this time.

Brant Biehn: Excellent. Thank you, Phil. Well, that wraps-up our questions for today. Ms. Terry , I hand it back to you.

Operator: Thank you. This will conclude today’s conference. You may disconnect your lines at this time. And thank you for your participation.